An Industry Analysis of the Impacts of the COVID-19 Pandemic on Medication Management Planning

[摘要] The COVID-19 pandemic threatens global corporate ties and dynamics in new ways. Because of its highly organized compliance efforts,pharmaceutical corporations' pharmacovigilance functions are especially vulnerable to shifting external demands. We performed anindustry-wide poll to get insight into how the pharmacovigilance function responded to the pandemic's issues. We examined the influence onportfolios and operational activity parameters of smaller and larger enterprises. The COVID-19 pandemic led the world to an unexpectedrealization of the coronavirus and its developing genome's significant, unprecedented threat to human health, organizational structures, andglobal commercial linkages and dynamics. Business continuity has become the catchphrase, and robustness and resilience are the desiredaims, but recognition of the pandemic's effects on systems at the granular level has been gradual. Since the 1970s, when the fundamentalmodel mostly represented a reactive approach to crisis management when faced with unforeseen challenges, the discipline of businesscontinuity has progressed dramatically. In the United States, for example, the White House Security Council created a National Strategy forPandemic Influenza in 2006 without explicitly including business continuity. In contrast, Ireland's Department of Enterprise, Trade, andEmployment deliberately addressed the problem of business continuity in 2007 by completing 12 case studies in several economic sectors,including food processing, financial services, and technology and medical equipment. Today, business continuity management is a distinctprofession, and the World Health Organization is in the third iteration of global health recommendations for business continuity planning inthe event of an influenza pandemic.

[学科分类] 药理学